Lupin Ltd (LUPIN) — Announcement | 28 September 2026 (2 announcements)

Lupin announced that its U.S. subsidiary received tentative FDA approval for a novel apixaban oral suspension formulation, expanding administration options for anticoagulation therapy. The product will be manufactured at Lupin's New Jersey facility upon final approval, reinforcing its U.S. manufacturing capabilities and portfolio diversification. This regulatory milestone supports growth in the cardiovascular segment and enhances market positioning for generic alternatives to Eliquis.

Lupin Ltd announced that its insider trading window will close on October 1, 2026, and remain shut until 48 hours after the unaudited Q2 results for September 30, 2026, which will be disclosed at a board meeting later. This restriction limits trading by designated persons and their relatives during a critical earnings period.